恩华药业：右酮洛芬氨丁三醇注射液获得《药品注册证书》

Core Viewpoint - Enhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of its injectable drug, R-ketorolac tromethamine, which is a non-steroidal anti-inflammatory analgesic used for acute moderate to severe postoperative pain in adults who cannot take oral medication [1] Group 1 - The drug R-ketorolac tromethamine acts as an inhibitor of COX-1 and COX-2 activities and is used as an adjunct to opioid analgesics [1] - The analgesic effect and safety profile of R-ketorolac tromethamine are reported to be good, significantly reducing the need for postoperative opioid medications [1] - Currently, only Nanjing Zhengke Pharmaceutical Co., Ltd. has received approval for this drug in the domestic market [1]